2. Others
  3. Others
  4. Belatacept

Belatacept  (Synonyms: BMS 224818; LEA 29Y)

Cat. No.: HY-108813 Purity: 98.00%
COA Handling Instructions

Molarity Calculator

Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants.

For research use only. We do not sell to patients.

Belatacept Chemical Structure

Belatacept Chemical Structure

CAS No. : 706808-37-9

Size Price Stock Quantity
1 mg USD 200 In-stock
5 mg USD 560 In-stock
10 mg USD 900 In-stock
50 mg USD 2880 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Belatacept Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants[1].

IC50 & Target

CD80/86[1]
In Vitro

Belatacept (0-5 mg/mL, 1 h) inhibits T-cell proliferation in a dose-dependent manner[2].
Belatacept (500 ng/mL, 7 days) enhances predominance of effector-memory T-cells after allogeneic stimulation[2].
Belatacept (100, 500 ng/mL, 7 days) has no effect on differentiation and allogeneic IFNγ production of isolated effector-memory T cells[2].
Belatacept (10?μg/mL, 1 h) does not inhibit follicular T Cell-dependent B-Cell differentiation[4].
Belatacept (40?μg/mL, 10 days) reduces plasmablast differentiation, Ig production, and the major transcription factor Blimp-1 in a T cell-independent manner[5].
Belatacept (40?μg/mL, 30 min) induces activation of the STAT3 transcription factor in stimulated B cells and reduced the expression of CD86[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Belatacept Related Antibodies

Cell Viability Assay[2]

Cell Line: PBMCs from healthy volunteers
Concentration: 0-5 mg/mL
Incubation Time: 1 h
Result: Inhibited T-cell proliferation l with IC50 values of 215 ng/mL, and residual T-cell proliferation (±30%) was still present at high doses.

Western Blot Analysis[5]

Cell Line: CD40L and IL-21 stimulated B cells
Concentration: 40 μg/mL
Incubation Time: 15, 30 min
Result: Increased in STAT signaling determined by increased STAT3 phosphorylation.
In Vivo

Belatacept (intraperitoneal injection, 60 mg/kg) inhibits ABMR (Antibody-Mediated Rejection), and inhibits acute rejection when combined with BTLA (B and T lymphocyte attenuator) overexpression therapy[3].
Belatacept (intravenous injection, 20 mg/kg) displays immunosuppressive activities in monkeys immunized with sheep red blood cell[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Acute rejection model of orthotopic kidney transplantation in rats[3]
Dosage: 60 mg/kg
Administration: Intraperitoneal injection, at postoperative and 4 days after transplantation.
Result: Inhibited creatinine increase after kidney transplantation (combined with BTLA overexpression therapy).
Reduced C4d in graft IF staining, and reduced CD138 infiltration and DSA production.
Animal Model: Rhesus monkeys immunized with sheep red blood cell[6]
Dosage: Intra-operatively 10 mg/kg, on day 4 (15 mg/kg) and on post-operative days 14, 28, 42, 56, 70 (20 mg/kg).
Administration: intravenous injection
Result: Caused a 50% reduction in the peak anti-SRBC response.
Prolonged renal allograft survival and synergies with conventional immunosuppression.
Clinical Trial
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

[Belatacept]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Store at 4°C, do not freeze
Purity & Documentation

Purity: 98.00%

COA (230 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Belatacept Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Belatacept706808-37-9BMS 224818 LEA 29YBMS224818BMS-224818OthersPBMCT-cellB cellseffector-memory T-cellskidney transplantationacute rejectionimmunosuppressantBTLAtransplantationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Belatacept
Cat. No.:
HY-108813
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.